Caplin Point Laboratories (524742) investor relations material

Executive summary

• Revenue grew by up to 20.7% year-over-year in Q1 FY27, with strong contributions from both emerging and US markets.

• EBITDA increased by 23% year-over-year, and PAT rose 18.8% to ₹179 Crores in Q1 FY27.

• The business model emphasizes vertical integration, digitalization, and expansion into regulated markets, supported by robust cash reserves and liquidity.

• Expansion plans include new factories, automation, and a focus on private and regulated markets in Latin America, North America, and other regions.

• Board recommended a final dividend of ₹4 per share for FY26, subject to AGM approval.

Financial highlights

• Q1 FY27 revenue reached ₹644 Crores, up 20.7% year-over-year; US revenue grew 26% to ₹137 Crores.

• Q1 FY27 EBITDA was ₹247 Crores, margin at 38.4%; gross margin was 59.8%.

• PAT for Q1 FY27 was ₹179 Crores, margin at 27.8%; basic EPS rose 15.8% to ₹23.27.

• Free cash reserves stood at ₹1,502 Crores; total liquid assets at ₹2,875 Crores as of June 30, 2026.

• Cash flow from operations in Q1 FY27 was ₹95 Crores; free cash flow after capex was ₹40 Crores.

Outlook and guidance

• Continued focus on expanding sterile manufacturing, oncology, and API capabilities, with new product launches and market entries in Mexico, Chile, Central America, and other regulated markets.

• Capex budget of over ₹1,000 Crores, with 50% nearing completion and the rest to be incurred over 2-3 years, funded by internal accruals.

• Anticipates maintaining gross margins near 60% and further EBITDA improvement.